Bli medlem
Bli medlem

Du är här

2016-02-23

Neurovive Pharmaceutical: Board Selects New CEO Erik Kinnman to Lead NeuroVive

NeuroVive Pharmaceutical AB (publ) board of directors is pleased to
announce that it has selected Erik Kinnman as NeuroVive's Chief
Executive Officer (CEO). Erik Kinnman will assume the new role on the
14th March 2016, leaving Chief Medical Officer (CMO) and Chief
Operating Officer (COO) roles within his own consultancy business.

Erik Kinnman is a seasoned life science executive with broad
experience and understanding from the industry across a variety of
businesses and functions. He has held a number of senior leadership
positions in biopharmaceutical companies such as AstraZeneca and
Sobi. His expertise and experience includes clinical development,
business strategy, business development, and investor relations. Erik
Kinnman also has experience from the financial sector. In addition,
he holds an Executive MBA from the Stockholm School of Economics and
has comprehensive scientific qualifications from the Karolinska
Institutet, which has rendered him a Ph.D. and an Associate
Professor. Moreover, Erik Kinnman is an M.D., board certified in
Neurology and Pain Management.

"The NeuroVive Board and I are confident that Erik Kinnman is the
right person to lead the company, its strategy, and leverage the
opportunities. The combination of his strategic vision and medical
expertise is an excellent fit with NeuroVive's strategy refocused
towards R&D. Erik Kinnman is a strong and experienced leader who has
a proven ability to translate scientific, clinical and business
strategy into execution," commented Gregory Batcheller, Chairman of
the NeuroVive Board of Directors. "He will provide expertise and
focus across the organization and establish solid partnerships that
will enhance our R&D program further. His broad experience grounded
in research, medicine and the biopharmaceutical industry is exactly
what we need to lead this organization forward."

"I am excited about NeuroVive, the CEO role, and the opportunity to
contribute to the success and growth of the company. NeuroVive is a
highly innovative organization and I am convinced that it has great
potential in its range of novel treatment opportunities and their
commercial potential. NeuroVive and its partners are truly led by a
purpose and passion to make a difference and meaningful impact to
patients affected by mitochondrial disorders. I will enable our
researchers and partners to deliver on the opportunities in the
clinical projects, as well as in the early pipeline to drive the
value of NeuroVive." says Erik Kinnman.

Erik Kinnman succeeds interim CEO Jan Nilsson, who will resume his
position as Chief Operating Officer for NeuroVive. Jan has made
significant contributions to move the organization forward. The
recent partnership deals with both Isomerase and the University of
Pennsylvania (UPENN) have been significant achievements under Jan's
leadership. Jan's extensive NeuroVive knowledge and commitment to
move the organization forward have been greatly appreciated by both
the teams and board of NeuroVive.

About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial
medicine and a company committed to the discovery and development of
highly targeted candidates that preserve mitochondrial integrity and
function in areas of significant therapeutic need. NeuroVive's
business approach is driven by value-adding partnerships with
mitochondrial research institutions and commercial partners across
the globe. NeuroVive's portfolio consists of two clinical projects in
acute kidney injury (AKI) and traumatic brain injury (TBI) with
candidates in clinical and preclinical development and two drug
discovery platforms. The NeuroSTAT? product has orphan drug status in
Europe and in the US for treatment of moderate to severe traumatic
brain injury and is currently being evaluated in a study, CHIC.
Ciclosporin is being evaluated in an on-going study, CiPRICS, in
acute kidney injury during major surgery. NeuroVive's shares are
listed on Nasdaq, Stockholm, Sweden.

For investor relations and media questions, please contact:
Christine Tadgell, NeuroVive, Tel: +46 (0)275 62 20 or
ir@neurovive.com

It is also possible to arrange an interview with NeuroVive's Chairman
Gregory Batcheller at the above contacts.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.com, www.neurovive.com

NeuroVive Pharmaceutical AB (publ) is required to publish the
information in this news release under The Swedish Securities Market
Act. The information was submitted for publication on 23 February
2016, at 08 30 CET.

NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine
company. The company is listed on NASDAQ OMX Stockholm, Small Cap,
under the ticker symbol NVP. The share is also traded on the OTC
market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the
OTC Pink Market. Investors can find Real-Time quotes and market
information for the company at www.otcmarkets.com/stock/NEVPF/quote
(http://htt://www.otcmarkets.com/stock/NEVPF/quot)

-----------------------------------------------------------
http://news.cision.com/neurovive-pharmaceutical/r/board-selects-new-ceo-...
http://mb.cision.com/Main/6574/9921655/480502.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.